Anti-TNF-Therapie des Morbus Bechterew

P . b . b . G Z 0 2 Z 0 3 1 1 0 8 M , V e r l a g s p o s t a m t : 3 0 0 2 P u r k e r s d o r f , E r s c h e i n u n g s o r t : 3 0 0 3 G a b l i t z Indexed in SCOPUS/EMBASE/Excerpta Medica www.kup.at/mineralstoffwechsel Österreichische Gesellschaft für Orthopädie und Orthopädische Chirurgie Österreichische Gesellschaft für Rheumatologie Offizielles Organ der Österreichischen Gesellschaft zur Erforschung des Knochens und Mineralstoffwechsels Member of the Anti-TNF-Therapie des Morbus

[1]  M. Dougados,et al.  First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis , 2005, Annals of the rheumatic diseases.

[2]  G. Kollias,et al.  Overexpression of TNF causes bilateral sacroiliitis , 2004 .

[3]  M. Dougados,et al.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.

[4]  M. Dougados,et al.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[5]  D. Baeten,et al.  Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? , 2003, Annals of the rheumatic diseases.

[6]  A. Zink,et al.  Validierung einer deutschen Version des Fragebogens BASDAI zur Messung der Krankheitsaktivität bei ankylosierender Spondylitis , 2003, Zeitschrift für Rheumatologie.

[7]  P. Mease.  Disease‐modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment , 2003, Current opinion in rheumatology.

[8]  E. Veys,et al.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.

[9]  A. Boonen,et al.  Ankylosing spondylitis: an overview , 2002, Annals of the rheumatic diseases.

[10]  M. Dougados,et al.  Conventional treatments for ankylosing spondylitis , 2002, Annals of the rheumatic diseases.

[11]  J. Braun,et al.  Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. , 2002, Clinical and experimental rheumatology.

[12]  B. Dijkmans,et al.  Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. , 2002, Clinical and experimental rheumatology.

[13]  S. van der Linden,et al.  Assessment of Functional Ability in Younger and Older Patients with Ankylosing Spondylitis: Performance of the Bath Ankylosing Spondylitis Functional Index , 2002, American journal of physical medicine & rehabilitation.

[14]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[15]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[16]  J. Braun,et al.  Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. , 2000, Arthritis and rheumatism.

[17]  M. Dougados,et al.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? , 1999, Rheumatology.

[18]  D. Reda,et al.  Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. , 1996, Arthritis and rheumatism.

[19]  J. Braun,et al.  Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. , 1995, Arthritis and rheumatism.

[20]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[21]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[22]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[23]  J. Gran,et al.  Epidemiology of ankylosing spondylitis. , 2008 .

[24]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[25]  M. Sadowska-Wroblewska,et al.  Clinical symptoms and signs useful in the early diagnosis of ankylosing spondylitis , 1983, Clinical Rheumatology.

[26]  J. Braun,et al.  [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. , 2003, Zeitschrift fur Rheumatologie.

[27]  C. Ritchlin.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha. , 2002, Current rheumatology reports.

[28]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[29]  I. Haslock.  Ankylosing spondylitis. , 1993, Baillière's Clinical Rheumatology.